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Abstract
Objective—To define the pharmacokinetic (PK) parameters of 17-hydroxyprogesterone caproate
(17-OHPC) in multifetal gestation.
Study Design—Blood was obtained at 24–28 weeks and at 32–35 weeks in 97 women with twin
and 26 women with triplet gestation receiving 17-OHPC. Six of the women with twins had daily
blood sampling for 7 days between 24 and 28 weeks and PK parameters were estimated using
noncompartmental analysis. Modeling was applied to estimate the population parameters and to
simulate various treatment scenarios.
Results—The apparent half-life of 17-OHPC was 10 days. BMI significantly impacted 17-
OHPC concentrations but fetal number and parity did not. Apparent clearance was significantly
greater in African American than in Caucasian women (p = 0.025).
Conclusions—This is the first pharmacokinetic analysis of 17-OHPC in pregnant women.
Determination of half life, covariates affecting plasma 17-OHPC concentrations and modeling of
drug behavior provide insights into this drug’s pharmacology during multifetal pregnancy.
Keywords
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Introduction
17-hydroxyprogesterone caproate (17-OHPC) reduces the rate of recurrent preterm birth in
women carrying a single fetus. This therapy has been evaluated in other conditions
associated with preterm birth including multifetal gestation,2,3,4 short cervix,5,6 and cervical
cerclage. 7, Despite widespread clinical use, no data exist describing the pharmacokinetics of
17-OHPC in pregnancy or the plasma concentrations achieved during therapy for preterm
birth prevention. In the current study, we evaluated the pharmacokinetics (PK) of 17-OHPC
in women with either a twin or triplet gestation who were receiving 17-OHPC in one of two
separate placebo controlled trials aimed at determining the utility of this agent in reducing
preterm birth.2,3 We also used population pharmacokinetic modeling to simulate plasma 17-
OHPC concentrations under various clinical conditions.
MATERIALS AND METHODS
Patients and Drug administration
A total of 661 women with twins and 134 women with triplet gestation were recruited into
two randomized controlled trials.2,3 Subjects received weekly injections of either 250 mg
17-OHPC in 1 ml castor oil or 1 ml castor oil alone from the time of enrollment (16 0/7
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weeks – 20 6/7 weeks) until 35 weeks unless delivered earlier. Data recorded for each
patient included maternal age, parity, race, BMI and gestational age at enrollment, as well as
gestational age at each blood sampling and at delivery. These data were evaluated as
covariates in the pharmacokinetic analysis. This study was approved by the institutional
review boards of each clinical site and of the data coordinating center. Consent was given
before enrollment into the study. The parent trials were registered at Clinical Trials.gov
(NCT00099164).2,3
Pharmacokinetic sampling schedule
Among subjects recruited for the primary randomized controlled trials and receiving all their
scheduled injections of 17-OHPC, 97 with twins and 53 with triplets were undelivered and
had a single blood sample drawn between 24–28 weeks (epoch1) for measurement of 17-
OHPC concentration. Among these women, 70 with twins and 26 with triplets were
undelivered and had a second sample taken at 32–35 weeks (epoch 2) for analysis. The
infrequent (sparse) sampling described above is useful in comparing plasma 17-OHPC
concentrations over time and between groups but does not lend itself to classic
pharmacokinetic analysis which requires frequent sampling during one dosing interval.
Fifteen of the 97 women with twins agreed to have a single blood sample taken daily for
seven consecutive days over a dosing interval of one week between 24–28 weeks (intensive
sampling). The first blood sample was drawn minutes prior to a scheduled injection.
Recruitment of these 15 women was masked to treatment arm; therefore women who
received either 17-OHPC or placebo were included. All of the fifteen women had received a
minimum of four weekly injections of 17-OHPC from the time of enrollment in anticipation
that steady state concentration in those women receiving 17-OHPC would be achieved by
the start of the PK study. Analysis of these plasma samples was not undertaken until
completion of the clinical trials so that masking of treatment arm was maintained
Sample Analysis
For all 17-OHPC measurements, blood was collected in 10 ml tubes with EDTA as the
anticoagulant and centrifuged within one hour at 3500 × g for 10 minutes. The supernatant
plasma was aliquoted to 1 ml tubes and frozen at −70 degrees centigrade until analyzed by
high performance liquid chromatography with tandem mass spectrometry (LC-MS). The
assay methodology has been reported.8 The lower limit of detection of the assay for 17-
OHPC was 1 ng/ml, inter and intra assay variability at 10 ng/ml were7.9 and 5.2%,
respectively. The analyst and the clinical centers involved in recruitment remained masked
to the treatment assignment until the analyses were completed.
Noncompartmental Pharmacokinetic Analysis
Nine of the 15 subjects who underwent “intensive sampling” (daily for seven days) had
received placebo and were therefore not included in the pharmacokinetic analysis though
their plasma samples had been analyzed. Pharmacokinetic parameters for the 6 subjects who
received 17-OHPC and underwent ‘’intensive sampling” were estimated using the standard
noncompartmental approach implemented in WinNonlin® (v. 4.0, Pharsight Corp.,
Mountain View, CA). Trough concentrations (Ctrough) maximum concentration (Cmax)
and time to maximum concentration (Tmax) were determined from the observed data. The
elimination rate constant (λz) was determined by log-linear regression of the terminal linear
disposition phase. Half-life (t1/2) was estimated by 0.693/ λz. Area under curve (AUC) was
calculated using the linear trapezoidal method. Apparent clearance [clearance (CL)/
bioavailability (F)] was estimated by Dose/(AUC), and the apparent volume of distribution
(VD/F) was calculated by Dose/( λz AUCinf).
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Population pharmacokinetics is the pharmacokinetic evaluation of patients who are
representative of the target patient population being treated with a medication. This
methodology is commonly used to define patient specific factors such as weight, race or sex
that contribute to the variability in drug concentrations. Large populations of subjects with
fewer samples taken from each subject can be analyzed with this methodology. With a
sufficiently large population, estimates of the impact of covariates on pharmacokinetic
parameters can be made without having to collect numerous samples from each subject. For
the current study, analysis was performed by means of non-linear mixed effects modeling
implemented in the Monolix® software. Both sparsely sampled and intensively sampled
data used in the non-compartmental analysis were included in the dataset.
Preliminary analysis for the structural model was performed by comparing one-compartment
model with two and three compartment models. A proportional error model was used for
describing residual variability. Interindividual variability was assumed to have a log-normal
distribution.The patient characteristics BMI, race, fetal number, and parity were evaluated as
covariates during the model building process as described by Lavielle and Mentre.9 The
goodness of fit of the final model was evaluated by inspecting the following charts:
scatterplots of predictions (population and individual) versus individual observations;
population weighted residuals versus predictions and independent variable (time); absolute
individual weighted residuals versus individual predictions. In addition, model validation
was performed using prediction distribution errors and visual predictive check, obtained by
conducting 1000 Monte Carlo simulations of the data set for the final model.9,10
Further, simulations were carried out based on the final model to evaluate the effect of
changes in BMI and dosing regimen on the plasma concentration time profiles of 17-OHPC.
Statistical Analysis
GraphPad Prism (4.01) was used for performing the statistical tests for significance. Non-
parametric (Mann Whitney U) tests were used for group comparisons. Kruskal-Wallis test
with Dunn’s multiple comparison was used for testing equality of population medians in
multiple groups. We considered p-values < 0.05 to be significant.
RESULTS
Pharmacokinetics (Intensive Sampling)
As expected, among the women who agreed to intensive (daily) sampling, 17-OHPC was
not detectable in the plasma of the 9 women who received placebo but was detectable in all
six women who had received 17-OHPC. Figure 1 depicts the mean (±SD) plasma
concentration of 17-OHPC in the six women with twins who had daily blood sampling over
a 7 day period. Average peak concentration (Cmax) of 17.3 ng/ml was noted at the first post
injection sample at 1 day. Over the ensuing 6 days, plasma concentrations declined slowly to
a nadir of 9.7 ng/ml at 7 days post injection. Selected pharmacokinetic parameters (mean,
SD and range) for 17-OHPC in these 6 subjects are summarized in Table 1. The apparent
half life was long at 10 days suggesting slow release from either the castor oil depots or
maternal fat. The wide range of AUC and Cmax values indicates considerable inter-
individual variation in absorption and metabolism of 17-OHPC. The peak concentration
(Cmax) occurred 1.2 days (Tmax) after the injection. The apparent volume of distribution
was large with considerable inter-individual variation. Apparent clearance varied two-fold
with a mean of 1204 l/day.
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We also evaluated whether steady state concentrations of 17-OHPC were achieved over the
course of therapy (Figure 2). For this analysis only women who received all their scheduled
injections and remained undelivered through epoch 2 (32–35 weeks) were included. This
included 70 women with twins and 12 women with triplets. Among these women, the mean
plasma concentrations of 17-OHPC were higher in epoch 2 than in epoch 1 for both the twin
and triplet groups and significantly so in the twin group (p=0.002). The mean time from first
injection to first blood draw was 43.2 (sd 12.5) days for twins and 45.0 (sd 12.0) days for
triplets. The mean time between first and second blood draw was 46.1 (sd 8.2) days for
twins and 44.3 (sd 5.8) days in women with triplets. Since plasma concentrations at epoch 2
(32–35 weeks) were higher than at epoch 1 (24–28 weeks) steady state concentrations were
not achieved by epoch 1.
Impact of BMI and other covariates on 17-OHPC concentrations
We evaluated the impact of pre-pregnancy BMI, race and parity on plasma 17-OHPC
concentrations only in women with twins. In this cohort we evaluated separately the 97
women who had received all their scheduled injections of 17-OHPC and remained
undelivered until the first blood sample was drawn between 24–28 weeks gestation (epoch
1) and the 70 women who received all their scheduled injections and remained undelivered
at the second blood draw at 32 – 35 weeks (epoch 2). A significant, (p<0.01) albeit weak
linear relationship (r=−0.28 for epoch 1 and −0.33 for epoch 2) was observed for plasma 17-
OHPC and BMI in women with twins (data not shown). Plasma concentrations of 17-OHPC
in African Americans (AA) in epoch 2 only were lower (p= 0.051) compared with
Caucasians (CA). Parity did not impact plasma 17-OHPC concentrations significantly in
either epoch.
Impact of Fetal Number of 17-OHPC Concentration
Concentrations of 17-OHPC (mean and median) did not differ significantly in women
carrying triplets compared with women carrying twins. This applied to both sample time
points (Figure 2).
Population Pharmacokinetics (POP-PK)
A total of seventy-one patients with twin gestation (65 in the sparsely sampled group and 6
in the intensively sampled group) who had at least two samples drawn during the study were
included in the POP-PK model building process. A total of 188 observational data points
were collected and utilized for this analysis. The data was best described by a one-
compartment model with first order absorption. Of the various covariates tested in building
the final model, BMI was observed to have a significant effect on the estimation of 17-
OHPC clearance and was included in the final model. Although race was not a significant
covariate in the final model, plasma clearance in African Americans was significantly higher
than in Caucasians (p<0.05) (Fig.3).
The estimates of the pharmacokinetic parameters for these 71 subjects and their respective
standard errors are shown in Table 2. The inter-individual variability (IIV) was observed to
be ~24% for clearance and ~49 % for volume of distribution. The correlation coefficients
between predicted vs observed concentrations of 17-OHPC for individual and population
estimates were 0.85 and 0.50, respectively. This indicates the model fit to be fairly good for
each individual subject data. The observed variability in plasma concentrations between
subjects was reduced when adjusted for covariates, but other variables not collected in the
study also could have contributed to the additional variability in plasma concentrations.
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We utilized pharmacokinetic parameters obtained by POP PK analysis to simulate plasma
17-OHPC concentrations under various clinical scenarios. Simulations were carried out to
explore the effect of changes in BMI and dosing regimen on the plasma concentration time
profiles of 17-OHPC (Figure 4). The plasma concentration of 17-OHPC varied significantly
with BMI (Figure 4a) showing a more than two-fold difference in concentration over the
BMI range seen in our subjects (18–45 kg/m2).
The impact of a loading dose on time needed to reach steady state concentrations was also
evaluated. A simulated loading dose of 1000 mg reached and maintained steady state within
one week (Figure 4b). The final simulated steady state concentrations achieved with a
loading dose of 1000 mg followed by weekly injections of 250 mg would be comparable to
those observed without a loading dose. We also evaluated the effect of changing the dosing
schedule on the concentration-time profile (Figure 4c). Administering a dose of 500 mg
once every 2 weeks achieved predicted steady state concentrations similar to those with a
250 mg weekly injection although peaks were about 15% higher and trough concentrations
were about 15% lower with the 500 mg dose.
Comment
This is the first report of plasma concentrations and pharmacokinetic analysis of 17-OHPC
in pregnant women.11 Only one other study has evaluated the pharmacokinetics of 17-
OHPC but that was in non-pregnant women.12Pharmacokinetic evaluation has not been
reported in pregnant women with singleton gestation receiving 17-OHPC, so this study in
women with multifetal gestations provides an opportunity to evaluate this medication in
pregnancy. Our data provide insight into the general pharmacological properties of this
agent. We have shown that the half-life of 17-OHPC is long, that plasma concentrations are
affected by maternal BMI but not by fetal number or parity. We also demonstrated higher
clearance and lower concentrations of the drug in African American compared with
Caucasian women. We have simulated plasma 17-OHPC concentrations and have
demonstrated how maternal BMI would affect plasma concentrations and how alternative
dosing regimens would affect targeted plasma concentrations.
The half life of 17-OHPC in twins was long at 10 days. This long half life coupled with our
demonstration that 17-OPHC is rapidly metabolized in vitro by human hepatocytes and liver
microsomes13 suggests that slow release from the castor oil depot or maternal body fat
determines terminal half-life of 17-OHPC rather than the drug’s metabolism or elimination
characteristics. A long half life is also seen in non-pregnant women and can be expected in
pregnant women with singleton gestation.
The time to achieve peak concentration of 17-OHPC was 3–7 days in non-pregnant
women12, whereas we noted peak concentrations at 1–2 days after an injection. We did not
sample prior to the 24 hours time point so it is possible that in women with twins, the peak
plasma concentrations after an intramuscular injection occurs before 24 hours in women
carrying twins. Nonetheless, it appears that the time to peak concentration after an
intramuscular injection is shorter in pregnant women than in non-pregnant women. This
finding is not unexpected as blood flow to most tissues in pregnancy is increased compared
with that in non-pregnant subjects. The rate of rise in plasma 17-OHPC concentrations is
slow compared with intramuscular injections of other drugs dissolved in water based
solvents.14 The castor oil solvent slowly releases the 17-OHPC. The time to rapidly achieve
the desired concentration would become more relevant if other indications requiring a rapid
onset of action of 17-OHPC are evaluated in clinical trials (eg treatment of preterm labor).
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We selected to obtain blood samples at two time points. The first at 24–28 weeks was
selected in anticipation that steady state would have been reached since women began their
injections between 16–20 weeks gestation. The second sample was obtained at 32–35 weeks
to evaluate whether the drug accumulated with repeated injections. Steady state
concentration however, was not achieved by the time of the first blood draw. The reason
steady state is not achieved is likely due to the continuous, slow release of 17-OHPC from
the castor oil depots which is augmented with each injection. The therapeutic concentration
for 17-OHPC has not been established, but once it is, a loading dose could be administered
if therapeutic concentrations need to be rapidly achieved.
In this study, the pharmacokinetic parameters calculated from compartmental analysis were
used to simulate 17-OHPC plasma concentration time profiles under multiple hypothetical
clinical scenarios. The simulations were based on pharmacokinetic parameters estimated
from population pharmacokinetic analysis and included all the samples (trough
concentrations and PK samples) and so are not constrained by the potential error in any half
life estimates based on the pharmacokinetic study. The simulations we performed from
women with twin gestation are useful in providing a perspective of the drug’s behavior in
pregnancy. With modeling, we were able to demonstrate a significant impact of BMI and
race on plasma 17-OHPC concentrations. The basis for these differences is unclear but the
racial differences in 17-OHPC clearance suggest the possibility that genetic factors may
influence 17-OHPC pharmacologic behavior. Once therapeutic concentrations of 17-OHPC
are determined, higher doses may be needed to achieve desired concentrations in obese
women and in African-American women to achieve desired concentrations.
Simulations were also conducted to determine other possible dosing strategies. For example,
we demonstrated that a dosing schedule of 500 mg administered once every two weeks
could be utilized to achieve plasma concentrations comparable to those achieved with the
currently utilized regimen of 250 mg weekly. This regimen would clearly improve patient’s
acceptability. However, this dosing schedule needs to be evaluated carefully since the peak/
trough fluctuations were greater in this case as compared to the 250 mg/week regimen.
Furthermore, these simulation data cannot be applied to women with a singleton gestation.
We also demonstrated with our simulations that, if there was clinical need to achieve target
steady state concentrations rapidly, this could be done with a loading dose. The issue of
safety of such an approach would require consideration.
Conclusions regarding 17-OHPC pharmacokinetics reached in women with multifetal
gestations may not be applicable to women with singleton gestations. However, the findings
in women with a twin or triplet gestation provide a basis for evaluating the impact of
covariates on the pharmacology of 17-OHPC in singleton gestations. Similar simulations
with ritodrine proved useful in defining the association between drug dose and side effects
and in demonstrating the harmful effects of rapid dose escalation.15
17-hydroxyprogesterone caproate is recommended as a treatment option for women with a
prior preterm birth.16 Vaginal progestins have not proven consistently effective in this
population17 so 17-OHPC continues to be the therapeutic option of proven benefit for this
indication.1 Despite the widespread use of this agent, very little pharmacologic information
exists as to the proper dosing regimen or the mechanism of action of the
drug.18,19, 20, 21, 22, 23 The currently utilized regimen of 250 mg injected intramuscularly
weekly is empiric. Our study indicates a wide inter-individual variation in the pharmacology
of 17-OHPC. Such wide variability suggests that the beneficial effect of 17-OHPC in
reducing preterm birth rates in singleton gestation may be further optimized with a drug
administration regimen that achieves the desired concentration.
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In conclusion, this is the first report of plasma concentrations of 17-hydroxyprogesterone
caproate in pregnant women. This report defines the pharmacokinetic behavior of 17-
hydroxyprogesterone caproate in women with twin gestation and the impact of BMI, race
and fetal number on plasma 17-OHPC concentrations. Whether substantive differences in
these observations will be seen in singleton gestation requires additional study.
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DEFINITIONS
Pharmacokinetics This term describes the time course of a drug in the body and
includes absorption , distribution, metabolism and elimination.
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In simple terms it is what the body does to an administered
drug.
Pharmacodynamics This describes the relationship between the pharmacological
response and the drug concentration. This includes physiologic
or biochemical effects of drugs on the body or on
microorganisms or parasites within or on the body.
Sparse sampling A technique by which a limited number of samples is obtained
from a large population of subjects taking the same medication
in order to make inferences about the drug or its response.
Intensive sampling This is typically done within a dosing interval in order to
characterize the pharmacokinetics of a drug in a given patient
One compartment
model
If a drug distributes instantaneously through out the entire body
it is said to exhibit a one compartment model.
Multi compartment
model
If a drug does not distribute instantaneously through out the
entire body it is said to exhibit a multi compartment model.
Under such a condition while the drug distributes
instantaneously to certain parts of the body, it takes a longer
time to reach other parts of the body.
Steady state
concentration
Steady state concentrations of a drug are achieved when the
rate at which a drug comes into the body equals the rate at
which the drug leaves the body. At steady state, the plasma
concentration of a drug is constant during continuous
intravenous infusion, or the plasma concentration versus time
profile during a dosing interval is identical to the plasma
concentration versus time profile during the subsequent dosing
intervals for a fixed dose and dosing frequency. Steady state
plasma concentrations are achieved in approximately 5–6 half
lives.
C max This is the highest concentration of a drug in blood or plasma
during a dosing interval after administration of a drug.
Tmax or T peak This is the time at which maximum blood or plasma




This is the area under the blood or plasma concentration versus
time curve for a drug.
Clearance This describes the over all ability of the body to clear the drug.
It is the volume of blood or plasma that is completely cleared of
the drug per unit time. The clearance is calculated as the
amount of drug cleared (for IV dose this will be dose) divided
by the area under the blood or plasma concentration versus
time.
Volume of distribution Volume of distribution is a hypothetical volume that relates the
concentration of the drug in the measured biological fluid
(normally plasma or serum or blood) to the amount of drug in
the body. In other word, it is the apparent volume into which
the drug has to be distributed at a concentration equal to the
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concentration measured in the biological fluid. It is typically
expressed in liters or in liters per kilogram. This parameter
provides information about the extent to which the drug is
distributed outside the vascular system.
Apparent Half-life This is a measure of the time that it takes for the drug
concentration to decrease from a given value to one half of its
value. It takes about 5–6 half lives for most of the drug to be




This is an approach that utilizes the pharmacokinetic
parameters of a drug and mathematical modeling to predict the




A problem solving technique used to approximate the
probability of certain outcomes by running multiple trial runs,




This describes the relationship between physiology and
pharmacokinetics and pharmacodynamics. Population
pharmacokinetics is the study of the sources and correlates of
variability in drug concentrations in the patient population
receiving clinically relevant doses of a drug of interest.
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Figure 1. Mean Plasma Concentration of 17-OHPC Following IM Injection of 250mg
17-OHPC concentration–time profiles for 6 subjects with twins who had sampling done
before and then daily for seven days after an injection. Values are mean (±) standard
deviation.
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Figure 2. Mean Plasma Concentrations of 17-OHPC in Twin and Triplet Gestation During Two
Gestational Epochs
Mean (±sd) 17-OHPC concentrations in the 70 subjects with twins and the 12 subjects with
triplets who had blood obtained during epoch 1 at 24–28 weeks and epoch 2 at 32–35 weeks.
Single asterisk indicates significant difference (p<0.002) between epoch1 and epoch 2 in
twins. Concentrations in twins vs triplets were statistically similar (p>0.05) both in epoch 1
and 2. Mann-Whitney test was used for the comparisons.
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Figure 3. 17-OHPC Clearance According to Race
A boxplot depicting the median 17-OHPC clearance (individual) estimates associated with
different ethnicities. The bars represent 25th (lower bar) and 75th (upper bar) percentile.
AA – African Americans (n=14), CA – Caucasians (n=46) and HIS – Hispanics (n=9). The
mean clearance in the Caucasians was significantly lower than that of African Americans
(p<0.05). The individual estimates were obtained with the final model which included BMI
as the covariate. Kruskal-Wallis one-way analysis of variance with Dunn’s post test was
used for the comparison.
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Figure 4. Simulated Plasma 17-OHPC Concentrations
Simulated plasma concentration time profiles of 17-OHPC in pregnant subjects. The bold
indicates the simulated plasma concentration utilizing a dose of 250 mg IM once weekly of
17-OHPC. The lighter line indicates simulated concentrations under various scenarios.
a. effect of BMI (18, 45 and 27) on plasma concentration time profiles,
b. effect of adding a loading dose of 1000 mg to the currently recommended regimen,
and
c. effect of changing the dosing schedule from 250 mg once weekly to 500 mg every
2 weeks.
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TABLE 2
Population Pharmacokinetic Parameter Estimates
Parameter Mean ± SE
Ka (day−1) 1.5 (Fixed)
V/F (×103 ltr) 62.5 ± 7.2
Cl/F (×103ltr/d) 1.29 ± 0.24
IIV_V 0.49 ± 0.13
IIV_Cl 0.24 ± 0.04
Population pharmacokinetic parameter estimates (mean ± SE) obtained from the final model. Ka: absorption rate constant, V/F: volume of
distribution/bioavailability, CL/F: apparent clearance/bioavailability, IIV: Interindividual variability in estimated pharmacokinetic parameters.
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